



# CURASEPT<sup>®</sup> IS HERE FOR YOU

COVID-19

PHASE 2

May 2020



# The Re-opening of Dental Practices - Curasept is here for you.

## Pre-procedural mouthrinses and COVID-19 transmission.

**Many recommendations and behavioural guidelines have been published in different countries by professional dental chambers and dental associations<sup>1-6</sup> to deal with the global pandemic due to the SARS-CoV-2 virus.**

**Covid-19 represents an infection of much more real concern to dentistry than to any other profession.**

In the report of the *US Bureau of Labour Statistics*, also covered intuitively and interactively by a publication in the *New York Times*<sup>7</sup>, it is mentioned that dentistry presents the greatest risk of exposure of medical practitioners to an infection, as they are brought in much closer contact with patients and patients' saliva.

**Great concern derives from the contaminated aerosol that dental procedures can generate. Of the various recommendations, one would appear to be of significant interest to the dental practitioner: the use of a mouthrinse as a possible safeguard to prevent cross infections, reduce aerosol contamination and inactivate the virus in the oral cavity.**

Only four papers<sup>10-13</sup> so far provide, mostly uneven and conflicting, recommendations for a preprocedural mouth rinse to reduce the polymicrobial load present in patients' saliva suggesting, according to the papers: povidone-iodine 1%, **hydrogen peroxide 1%**, **chlorhexidine**, cetylpyridinium chloride (CPC) 0.1% and essential oils.

Chlorhexidine has a well-documented activity against viruses in general and specifically against enveloped viruses (HIV<sup>18</sup>). Moreover, the **review by Lim and Kam<sup>19</sup> shows that chlorhexidine has an excellent virucidal action, even against coronaviruses, at even lower concentrations than those tested in the two previously cited studies<sup>16-17</sup>.**

Recently, in one of the first study performed on SARS-Cov-2, **Chin and collaborators<sup>20</sup> demonstrated**, in a laboratory test, the **virucidal efficacy of chlorhexidine at standard working concentration in a surface disinfectant formulation**. They concluded that SARS-CoV-2 can be highly stable in a favourable environment, but it is also susceptible to standard disinfection methods like chlorhexidine and other commonly used disinfectants.

Concluding: There is no definite proof that hydrogen peroxide 1% and povidone-iodine 1% are effective when used as mouth rinses against the SARS-CoV-2 virus, but their underlying oxidation mechanism can inactivate numerous Coronaviridae viruses from contaminated surfaces and areas. Moreover **Chlorhexidine** has certainly been proven to reduce the presence of microorganisms in the aerosol produced by dental procedures<sup>21</sup> and **has the highest substantivity and efficacy as a chemical plaque control agent<sup>22</sup>. Chlorhexidine can therefore also be a valid aid for preoperative rinses.**

These considerations suggest, as **some guidelines have proposed<sup>6</sup>, a double rinse with an oxidative agent followed by a broad-spectrum antiseptic.**

Since povidone-iodine 1% (an oxidative agent) has some contraindications (in the case of pregnancy, kidney failure, thyroid disease or concomitant drug therapies) and can be inactivated by other concomitant oral disinfectant<sup>23</sup>, the most appropriate rinse procedure seems to be:

- 1. First gargle with 1% hydrogen peroxide mouthwash for at least 15 seconds with a final rinse of 30 seconds.**
- 2. Followed by a rinse with 0.20% chlorhexidine mouthrinse for at least 60 seconds and then gargle for at least 15 seconds<sup>24</sup>.**

It is important to respect the duration of the rinses and especially the order given above to obtain the properties given by each antiseptic. It should also be highlighted that it is not, however, appropriate to combine the two products in a single rinse because, although chlorhexidine and hydrogen peroxide can coexist<sup>25</sup>, no studies have still assessed a self-made mixture against SARS-CoV-2 virus or the possible reduction of their activity in such a mix.

**This association would be able to provide a double mechanism of action, oxidative and broad spectrum antiseptic, providing an important reduction of the oral microbial load and a lower risk of environmental contamination through the aerosol produced by the rotating instruments. Curasept, following international indications and literature, is now able to provide the dental all the necessary solutions for protection required by the protocols for the reopening of the activity in Phase 2.**



## Bibliography

1. [www.fnomceo.it](http://www.fnomceo.it) Regional Federation of Associations of Doctors, Surgeons and Dentists of Lombardy. Coronavirus: indications for dentists in Lombardy. [Consulted 8 March 2020].
2. [www.ada.org](http://www.ada.org) American Dental Association. COVID-19 Resources for Dentists. [Consulted 4 April 2020].
3. [www.ada.com.au](http://www.ada.com.au) Australian Dental Association. Managing COVID-19 Guidelines; Last Update 25 March 2020. [Consulted 4 April 2020].
4. [www.fdiworlddental.org](http://www.fdiworlddental.org) COVID-19 guidelines from researchers based in Wuhan, China. [Consulted 2 April 2020].
5. [www.who.org](http://www.who.org) World Health Organization. Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19). Interim guidance. [Consulted 1 April 2020].
6. [www.sidp.it](http://www.sidp.it) Italian Society of Periodontology and Implantology & Various Authors. COVID-2019: Standards for dental activity. [Consulted 12 March 2020].
7. <https://www.nytimes.com/interactive/2020/03/15/business/economy/coronavirus-worker-risk.html> Bureau of Labour Statistics, O\*Net. [Consulted 24 March 2020].
8. Wölfel R, Corman V, Guggemos W, Seilmaier M, Zange S, Müller M, Niemeyer D, Jones T, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann R, Zwirgmaier K, Drosten C, Wendtner C Virological Assessment of Hospitalized Patients With COVID-2019 Nature 2020 Apr 1 [Online ahead of print]. DOI: 10.1038/s41586-020-2196-x.
9. Van Doremalen, N.; Bushmaker, T.; Morris, D.; Holbrook, M.; Gamble, A.; Williamson, B.; Tamin, A.; Harcourt, J.; Thornburg, N.; Gerber, S.; et al. Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. N. Engl. J Med. 2020; Mar 17. doi: 10.1056/NEJMc2004973.
10. Li ZY, Meng LY. The prevention and control of a new coronavirus infection in department of stomatology. [Article in Chinese]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2020 Feb; 14;55(0):E001.
11. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020 Mar 3;12(1):9.
12. Meng L., Hua F, Bian Z. Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine J Dent Res ,2020 Mar 12.
13. Ge ZY, Yang LM, Xia JJ, Fu XH, Zhang YZ. Possible aerosol transmission of COVID-19 and special precautions in dentistry. Journal of Zhejiang University 2020 ISSN 1673-1581 (Print); ISSN 1862-1783 (Online). <https://doi.org/10.1631/jzus.B2010010>
14. Sabino-Silva R, Gomes Jardim AC, Siqueira WL. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. Clin Oral Invest 2020, <https://doi.org/10.1007/s00784-020-03248-x>
15. Ather A, Patel B, Ruparel NB, Diogenes A, Hargreaves KM. Coronavirus Disease 19 (COVID-19): Implications for Clinical Dental Care. Journal of Endodontics, 2020 46(5): in press on 1st April 2020.
16. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of Coronaviruses on Inanimate Surfaces and Their Inactivation With Biocidal Agents Review J Hosp Infect, 104 (3), 246-251 Mar 2020.
17. Geller C, Varbanov M and Duval R E Human Coronaviruses: Insights into Environmental Resistance and Its Influence on the Development of New Antiseptic Strategies Review Viruses 2012, 4, 3044-3068; doi:10.3390/v4113044.
18. Lindhe J., Karring T. and Lang N.P. Clinical Periodontology and Implant Dentistry. 4th Ed., Vol. 2, Chapter 22., pag. 476, Blackwell Munksgaard, 2003.
19. Lim KS, Kam PCA. Chlorhexidine - Pharmacology and clinical applications. Anaesth Intensive Care 2008; 36: 502-512.
20. Chin ACW, Chu JTS, Perera MRA, Hui KPY, Yen HL, Chan MCW, Peiris M, Poon LLM. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe 2020; Published Online. April 2, 2020. [https://doi.org/10.1016/S2666-5247\(20\)30003-3](https://doi.org/10.1016/S2666-5247(20)30003-3).
21. Marui VC, Souto MLS, Rovai ES, Romito GA, Chambrone L, Pannuti CM. Efficacy of preprocedural mouthrinses in the reduction of microorganisms in aerosol: A systematic review. J Am Dent Assoc. 2019 Dec;150(12):1015-1026.e1.
22. Van der Weijden FA, Van der Sluijs E, Ciancio SG, Slot DE Can Chemical Mouthwash Agents Achieve Plaque/Gingivitis Control? Dent Clin North Am, Oct 2015 59 (4), 799-829.
23. [https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer\\_000020\\_023907\\_FI.pdf&retry=0&sys=m0b113](https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000020_023907_FI.pdf&retry=0&sys=m0b113) AIFA. Package informative sheet: information for the user: BETADINE 1% mouthrinse. Updated 3 January 2020. Consulted 25 March 2020.
24. Basso M, Bordini G, Bianchi F, Prosper L, Testori T, Del Fabbro M. Utilizzo di collutori preoperativi contro il virus SARS-CoV-2 (COVID-19): revisione della letteratura e raccomandazioni cliniche, Quintessenza Internazionale, 1/20 Marzo 2020
25. Mathurasai W, Thanyasrisung P, Sooampon S, Ayuthaya BIN. Hydrogen peroxide masks the bitterness of chlorhexidine mouthwash without affecting its antibacterial activity Indian Soc Periodontol. 2019 Mar-Apr; 23(2): 119-123.



300 ml bottle with measuring cup  
PROFESSIONAL ONLY

### **MOUTHWASH H<sub>2</sub>O<sub>2</sub>**

---

Mouthwash for professional use indicated to make rinse the patient before sitting.

Ready to use.

**HYDROGEN PEROXIDE 1%**

.....

.....

.....

.....

.....

.....

.....



900 ml bottle  
PROFESSIONAL ONLY

### **CURASEPT ADS 220 MOUTHWASH INTENSIVE**

---

Treatment for the prevention of post-operative complications and to decrease bacterial aerosol.

To be used after a first rinse with Curasept H<sub>2</sub>O<sub>2</sub>.

**CHLOREXIDINE DIGLUCONATE 0.20% WITH ADS**

.....

.....

.....

.....

.....

.....

.....



---

## INFO



[www.curaseptworldwide.com](http://www.curaseptworldwide.com)